Patent SG-11201408521W-A (SG)
Title: Use of ferric citrate in the treatment of chronic kidney disease patients
Inventor: PORADOSU ENRIQUE
IPC: A61K31/295
Filed: 2013-06-21
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2013 (27.12.2013) WIPOIPCT (10) International Publication Number WO 2013/192565 A2 (51) International Patent Classification: A61K31/295 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/047134 21 June 2013 (21.06.2013) English English (30) Priority Data: 61/662,565 61/757,229 61/801,050 61/800,618 21 June 2012 (21.06.2012) US 28 January 2013 (28.01.2013) US 15 March 2013 (15.03.2013) US 15 March 2013 (15.03.2013) US (71) Applicant: KERYX BIOPHARMACEUTICALS, INC. [US/US]; 750 Lexington Avenue, 20th Floor, New York, NY 10022 (US). (72) Inventors: PORADOSU, Enrique; 42 Verndale Street, Apt. Brookline, Massachusetts 1, 02446 (US). BENTSUR, Ron; 212 Highwood Avenue, Tenafly, New Jersey 07670 (US). OLIVIERO III, James F.; 30 West Street, Apt. 32E, New York, NY 10004 (US). (74) Agents: VINNOLA, Milan M. et al.; Dorsey & Whitney LLP, 1400 Wewatta, Suite 400, Denver, Colorado 80202- 5549 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the identity of the inventor (Rule 4.17(i)) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ CJ o\ i-H o CJ (54) Title: USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS (57) Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), in - crease hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.